Themis Medicare Ltd

Themis Medicare Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 April 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Themis Medicare Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 6 April 2026, reflecting a nuanced shift in its technical outlook despite persistent financial headwinds. This change is driven primarily by improvements in technical indicators, while fundamental and valuation metrics continue to weigh on the stock’s prospects.

Themis Medicare Ltd has exhibited a subtle shift in price momentum, moving from a bearish to a mildly bearish technical trend, reflecting a nuanced change in investor sentiment. Despite a modest day gain of 1.84%, the stock remains under pressure with mixed signals from key technical indicators such as MACD, RSI, and moving averages, underscoring a cautious outlook for this micro-cap pharmaceutical player.

A sharp decline in Themis Medicare Ltd has pushed the stock to a fresh 52-week low of Rs 68.15 on 30 Mar 2026, marking a continuation of recent losses that have seen the share price fall by 7.53% over the last two sessions. This drop comes amid a broader market downturn, but the stock’s underperformance is notably more severe than the benchmark indices.

Themis Medicare Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 15 Feb 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 30 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

A sharp decline of 7.58% in intraday trading dragged Themis Medicare Ltd to a fresh 52-week low of Rs 69.5 on 27 Mar 2026, extending its downward spiral amid broader market weakness.

A sharp decline of over 60% from its 52-week high has dragged Themis Medicare Ltd to a fresh 52-week low of Rs 70.52 on 24 Mar 2026, underscoring persistent selling pressure amid deteriorating fundamentals and subdued market sentiment.

A sharp decline of 4.17% today dragged Themis Medicare Ltd to a fresh 52-week low of Rs 72.39, extending a downward trajectory that has seen the stock lose over half its value in the past year.

Themis Medicare Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 15 Feb 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 19 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Themis Medicare Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a fresh 52-week low of Rs.73.63 today, marking a significant decline amid ongoing downward momentum. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in both its financial performance and market sentiment.

Themis Medicare Ltd has reached a new 52-week low of Rs.73.79 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on its financial performance and market valuation.

Themis Medicare Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 15 Feb 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 09 March 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and market standing.

Themis Medicare Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 15 February 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Themis Medicare Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 15 February 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 14 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.

Themis Medicare Ltd recorded a robust intraday performance on 3 Feb 2026, surging 7.03% to touch a day’s high of Rs 84.99, significantly outperforming its sector and the broader market amid mixed market conditions.

Themis Medicare Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 15 February 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 03 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.